Revance Therapeutics, Inc. - Common Stock (RVNC)
Frequently Asked Questions About Revance Therapeutics, Inc. - Common Stock (RVNC)
How does Revance prioritize sustainability or corporate social responsibility?
Revance Therapeutics actively prioritizes sustainability and corporate social responsibility (CSR) by implementing environmentally friendly practices in its operations and engaging in community outreach initiatives. The company strives to support health equity and access to care, considering its impact on both patients and the communities it serves.
How does Revance Therapeutics aim to address global health needs?
Revance Therapeutics aims to address global health needs by developing innovative therapeutic solutions for underserved patient populations across aesthetic and medical conditions. The company's strategy includes identifying and targeting indications with high unmet needs, conducting rigorous clinical research, and ensuring that its products are accessible to patients worldwide.
How does Revance Therapeutics differentiate itself from competitors?
Revance Therapeutics differentiates itself through its proprietary long-acting formulation of botulinum toxin, which offers extended duration of effect compared to existing products in the market. The company's emphasis on patient experience, innovative delivery mechanisms, and comprehensive clinical research investments also set it apart from competitors in the biotech space.
Is Revance Therapeutics publicly traded?
Yes, Revance Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol RVNC. The company went public in 2019, and its shares are actively traded, providing investors an opportunity to participate in the growth of the company and its innovative product pipeline.
What are the therapeutic applications of Revance's products?
Revance Therapeutics focuses on both aesthetic and therapeutic applications of its products. Therapeutically, its formulations are aimed at treating various conditions such as chronic migraine, cervical dystonia, and spasticity, among others. The company's commitment to both areas allows it to address a wide range of patient needs.
What does Revance Therapeutics, Inc. do?
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings in the field of neuromodulators and specialty biopharmaceuticals. The company develops and commercializes advanced formulations and delivery technologies to address unmet needs in various markets, primarily targeting aesthetic indications like facial wrinkles and therapeutic indications such as chronic pain and movement disorders.
What financial information should investors know about Revance?
Investors interested in Revance Therapeutics should be aware of key financial metrics including revenue trends, research and development expenditures, and net income or losses. As a biotechnology company, Revance typically incurs significant R&D costs as it advances its product pipeline. It's important for potential investors to stay updated with quarterly earnings reports and company announcements for the latest financial insights.
What investor resources does Revance offer?
Revance Therapeutics provides a variety of resources for investors, including a dedicated investor relations website that offers financial reports, stock performance data, corporate presentations, and details about upcoming events such as earnings calls and investor conferences. This transparency aids investors in making informed decisions regarding their investment in the company.
What is Revance's competitive advantage in the biotech sector?
Revance Therapeutics' competitive advantage in the biotech sector lies in its innovative product formulations and longer-lasting therapies compared to traditional options. The unique delivery and extended effect profile give it a notable edge in the aesthetics market, while its robust pipeline including therapeutic indications enhances its positioning against competitors. This combination of innovation and diversification aligns with industry trends and patient needs.
What is the company’s mission?
Revance Therapeutics' mission is to transform the lives of patients through innovative and differentiated products in aesthetics and therapeutics. The company is dedicated to developing evidence-based solutions that address unmet medical needs and enhance the quality of life for individuals affected by various conditions.
What is the main product of Revance Therapeutics?
Revance is best known for its flagship product, DaxibotulinumtoxinA injection, marketed under the brand name DaxibotulinumtoxinA for injection. This neuromodulator is designed for aesthetic applications, specifically for reducing the appearance of frown lines, as well as therapeutic applications for conditions like chronic migraine and cervical dystonia.
What is the status of Revance's clinical trials?
Revance Therapeutics is committed to advancing its pipeline of clinical trials for both aesthetic and therapeutic indications. The company regularly updates the status of its trials, which include Phase 3 studies for DaxibotulinumtoxinA and explorations of new applications. This commitment to rigorous clinical research underscores its dedication to product efficacy and safety.
What kinds of partnerships does Revance Therapeutics engage in?
Revance Therapeutics actively seeks partnerships and collaborations with other biopharmaceutical companies, research institutions, and industry stakeholders. These partnerships often focus on co-developing new technologies, expanding clinical trial capabilities, and entering new markets, amplifying the company’s reach and accelerating development timelines for its products.
What recent developments has Revance announced?
As of late 2023, Revance Therapeutics has announced several significant developments, including the successful launch of its expansion into international markets with its DaxibotulinumtoxinA products and ongoing clinical trials aimed at new therapeutic indications. These developments are part of the company's strategy to broaden its treatment portfolio and enhance its global footprint in the aesthetic and therapeutic markets.
What unique technology does Revance utilize in its products?
Revance Therapeutics utilizes its proprietary DaxibotulinumtoxinA technology platform, which allows for a longer duration of effect compared to traditional botulinum toxin injections. This platform features a proprietary formulation that enhances the delivery and stability of the product while minimizing the need for frequent treatments, thereby improving patient convenience and satisfaction.
When can we expect new product launches from Revance?
Revance Therapeutics regularly evaluates its product pipeline for potential launches, which can vary based on clinical trial outcomes and regulatory approvals. The company has indicated ongoing efforts to expand its portfolio, with expectations of new product launches in both aesthetic and therapeutic realms throughout 2024 and beyond.
When was Revance Therapeutics founded?
Revance Therapeutics, Inc. was founded in 2011 with the aim of advancing the field of biotechnology through the development of innovative therapies. Since its inception, the company has grown significantly, driven by its commitment to research and development in the aesthetic and therapeutic sectors.
Where is Revance Therapeutics, Inc. headquartered?
Revance Therapeutics, Inc. is headquartered in Nashville, Tennessee. The location allows the company to leverage a vibrant health care ecosystem, including access to leading clinical research institutions, which supports its commitment to developing cutting-edge therapies that benefit patients.
Who are the key executives at Revance Therapeutics?
Revance Therapeutics is led by a team of experienced executives in the biotechnology space. Key leaders include the CEO, who has extensive experience in drug development and commercialization, and other executive team members who bring expertise in regulatory affairs, clinical development, and financial management, all contributing to the company's strategic growth and innovation.
What is the current price of Revance Therapeutics, Inc. - Common Stock?
The current price of Revance Therapeutics, Inc. - Common Stock is 3.650
When was Revance Therapeutics, Inc. - Common Stock last traded?
The last trade of Revance Therapeutics, Inc. - Common Stock was at 4:00 pm EST on February 5th, 2025
What is the market capitalization of Revance Therapeutics, Inc. - Common Stock?
The market capitalization of Revance Therapeutics, Inc. - Common Stock is 262.18M
How many shares of Revance Therapeutics, Inc. - Common Stock are outstanding?
Revance Therapeutics, Inc. - Common Stock has 71.83M shares outstanding.